• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Should we take into account ESBLs in empirical antibiotic treatment?

作者信息

Bassetti Matteo, Rodríguez-Baño Jesús

机构信息

Infectious Diseases Division, Santa Maria Misericordia University Hospital, Udine, Italy.

Clinica Malattie Infettive, Azienda Ospedaliero-Universitaria "Santa Maria Della Misericordia", Piazzale S. Maria Della Misericordian. 15, 33100, Udine, Italy.

出版信息

Intensive Care Med. 2016 Dec;42(12):2059-2062. doi: 10.1007/s00134-016-4599-6. Epub 2016 Oct 21.

DOI:10.1007/s00134-016-4599-6
PMID:27770171
Abstract
摘要

相似文献

1
Should we take into account ESBLs in empirical antibiotic treatment?在经验性抗生素治疗中我们应该考虑超广谱β-内酰胺酶吗？
Intensive Care Med. 2016 Dec;42(12):2059-2062. doi: 10.1007/s00134-016-4599-6. Epub 2016 Oct 21.
2
Point-Counterpoint: Piperacillin-Tazobactam Should Be Used To Treat Infections with Extended-Spectrum-Beta-Lactamase-Positive Organisms.正反方观点：哌拉西林他唑巴坦应被用于治疗产超广谱β-内酰胺酶阳性菌感染。
J Clin Microbiol. 2018 Feb 22;56(3). doi: 10.1128/JCM.01917-17. Print 2018 Mar.
3
Comparative in vitro activity of beta-lactam/beta-lactamase inhibitor combinations against gram negative bacteria.β-内酰胺/β-内酰胺酶抑制剂组合对革兰氏阴性菌的体外比较活性
Indian J Med Res. 2005 Nov;122(5):425-8.
4
Editorial commentary: Bloodstream infection caused by extended-spectrum β-lactamase-producing Gram-negative bacteria: how to define the best treatment regimen?编辑评论：产超广谱β-内酰胺酶革兰氏阴性菌引起的血流感染：如何确定最佳治疗方案？
Clin Infect Dis. 2015 May 1;60(9):1326-9. doi: 10.1093/cid/civ007. Epub 2015 Jan 13.
5
Antibiotic policy and prescribing strategies for therapy of extended-spectrum beta-lactamase-producing Enterobacteriaceae: the role of piperacillin-tazobactam.产超广谱β-内酰胺酶肠杆菌科细菌治疗的抗生素政策与处方策略：哌拉西林-他唑巴坦的作用
Clin Microbiol Infect. 2008 Jan;14 Suppl 1:181-4. doi: 10.1111/j.1469-0691.2007.01864.x.
6
Activity of beta-lactam beta-lactamase inhibitor combinations against extended spectrum Beta-lactamase producing Enterobacteriaceae in urinary isolates.β-内酰胺类与β-内酰胺酶抑制剂联合制剂对尿液分离株中产超广谱β-内酰胺酶肠杆菌科细菌的活性
J Coll Physicians Surg Pak. 2012 Jun;22(6):358-62.
7
Antibiotic resistance: to the rescue of old drugs.抗生素耐药性：旧药的救赎
Nature. 2014 Jun 26;510(7506):477-8. doi: 10.1038/510477a.
8
Focus on ceftazidime-avibactam for optimizing outcomes in complicated intra-abdominal and urinary tract infections.关注头孢他啶-阿维巴坦以优化复杂性腹腔内感染和尿路感染的治疗效果。
Expert Opin Investig Drugs. 2015;24(9):1261-73. doi: 10.1517/13543784.2015.1062873. Epub 2015 Jul 6.
9
A resurgence of β-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens.β-内酰胺酶抑制剂复方制剂对抗多重耐药革兰氏阴性病原体的卷土重来。
Int J Antimicrob Agents. 2015 Nov;46(5):483-93. doi: 10.1016/j.ijantimicag.2015.08.011. Epub 2015 Sep 25.
10
Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination.头孢洛扎/他唑巴坦：一种新型头孢菌素/β-内酰胺酶抑制剂组合
Pharmacotherapy. 2015 Jul;35(7):701-15. doi: 10.1002/phar.1609. Epub 2015 Jul 1.

引用本文的文献

1
Increase in Incidence Rates and Risk Factors for Multidrug Resistant Bacteria in Septic Children: A Nationwide Spanish Cohort Study (2013-2019).脓毒症患儿多重耐药菌发病率及危险因素的增加：一项西班牙全国队列研究（2013 - 2019年）
Antibiotics (Basel). 2023 Nov 14;12(11):1626. doi: 10.3390/antibiotics12111626.
2
Factors associated with bacteraemia due to multidrug-resistant organisms among bacteraemic patients with multidrug-resistant organism carriage: a case control study.携带多重耐药菌的菌血症患者中多重耐药菌导致菌血症的相关因素：病例对照研究。
Antimicrob Resist Infect Control. 2018 Sep 29;7:116. doi: 10.1186/s13756-018-0412-3. eCollection 2018.
3

本文引用的文献

1
A Clinical Decision Tree to Predict Whether a Bacteremic Patient Is Infected With an Extended-Spectrum β-Lactamase-Producing Organism.一种用于预测菌血症患者是否感染产超广谱β-内酰胺酶病原体的临床决策树。
Clin Infect Dis. 2016 Oct 1;63(7):896-903. doi: 10.1093/cid/ciw425. Epub 2016 Jun 28.
2
A Multinational, Preregistered Cohort Study of β-Lactam/β-Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae.一项关于β-内酰胺/β-内酰胺酶抑制剂联合治疗产超广谱β-内酰胺酶肠杆菌科细菌所致血流感染的多中心、预注册队列研究。
Antimicrob Agents Chemother. 2016 Jun 20;60(7):4159-69. doi: 10.1128/AAC.00365-16. Print 2016 Jul.
3
Focus on severe infections.
关注严重感染。
Intensive Care Med. 2017 Jul;43(7):1033-1036. doi: 10.1007/s00134-017-4835-8. Epub 2017 May 13.
Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study.
厄他培南治疗产超广谱β-内酰胺酶肠杆菌科细菌所致血流感染：一项多国预注册队列研究。
J Antimicrob Chemother. 2016 Jun;71(6):1672-80. doi: 10.1093/jac/dkv502. Epub 2016 Feb 22.
4
Colonization and infection with extended-spectrum β-lactamase-producing Enterobacteriaceae in ICU patients: what impact on outcomes and carbapenem exposure?重症监护病房患者中产超广谱β-内酰胺酶肠杆菌科细菌的定植与感染：对预后及碳青霉烯类药物暴露有何影响？
J Antimicrob Chemother. 2016 Apr;71(4):1088-97. doi: 10.1093/jac/dkv423. Epub 2016 Jan 10.
5
Critically ill migrants with infection: diagnostic considerations for intensive care physicians in Europe.感染的危重症移民：欧洲重症监护医师的诊断考量
Intensive Care Med. 2016 Feb;42(2):245-8. doi: 10.1007/s00134-015-4090-9.
6
Diagnosis and antimicrobial treatment of invasive infections due to multidrug-resistant Enterobacteriaceae. Guidelines of the Spanish Society of Infectious Diseases and Clinical Microbiology.耐多药肠杆菌科细菌所致侵袭性感染的诊断与抗菌治疗。西班牙传染病与临床微生物学会指南
Enferm Infecc Microbiol Clin. 2015 May;33(5):337.e1-337.e21. doi: 10.1016/j.eimc.2014.11.009. Epub 2015 Jan 15.
7
Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalized in intensive care units in United States and European hospitals (2009-2011).美国和欧洲医院重症监护病房住院患者分离的革兰氏阴性菌的抗菌药物敏感性（2009-2011 年）。
Diagn Microbiol Infect Dis. 2014 Apr;78(4):443-8. doi: 10.1016/j.diagmicrobio.2013.11.025. Epub 2013 Dec 6.
8
A Review of Ten Years of the Study for Monitoring Antimicrobial Resistance Trends (SMART) from 2002 to 2011.十年监测抗菌药物耐药趋势研究（SMART）回顾：2002 年至 2011 年。
Pharmaceuticals (Basel). 2013 Nov 1;6(11):1335-46. doi: 10.3390/ph6111335.
9
Clinical impact and risk factors for colonization with extended-spectrum β-lactamase-producing bacteria in the intensive care unit.重症监护病房中产超广谱β-内酰胺酶细菌定植的临床影响和危险因素。
Intensive Care Med. 2012 Nov;38(11):1769-78. doi: 10.1007/s00134-012-2675-0. Epub 2012 Aug 15.
10
Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy.产碳青霉烯酶肺炎克雷伯菌血流感染患者的死亡率预测因素：联合治疗的重要性。
Clin Infect Dis. 2012 Oct;55(7):943-50. doi: 10.1093/cid/cis588. Epub 2012 Jul 2.